| Old Articles: <Older 4981-4990 Newer> |
 |
The Motley Fool July 21, 2008 Brian Lawler |
Amgen Rolls the Dice The Food and Drug Administration's impending ruling will determine the drugmaker's near-term fate. Investors, take note.  |
The Motley Fool July 21, 2008 Brian Lawler |
Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own.  |
The Motley Fool July 18, 2008 Brian Lawler |
Still Liking Gilead, Warts and All Don't look past a few issues, even though Gilead still has a bright future.  |
The Motley Fool July 18, 2008 Brian Orelli |
Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news.  |
The Motley Fool July 18, 2008 Brian Orelli |
What Strikes Against Stryker? High growth isn't enough to impress investors.  |
The Motley Fool July 18, 2008 Brian Orelli |
St. Jude Is a Fighter The medical device maker continues to kick the competition while it's down.  |
The Motley Fool July 18, 2008 Rich Duprey |
More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry.  |
Chemistry World July 17, 2008 Hepeng Jia |
Millions Raised for Drug Development China has launched its first biotech investment consortium.  |
The Motley Fool July 17, 2008 Brian Orelli |
Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release  |
The Motley Fool July 16, 2008 Brian Lawler |
A Big Move From ViroPharma ViroPharma picks up an asset that's more than half its size.  |
| <Older 4981-4990 Newer> Return to current articles. |